Conjugating 4 beta-NH-(5-Aminoindazole)-podophyllotoxin and Galectin-1-Targeted Aptamer for Synergistic Chemo-Immunotherapy of Hepatocellular Carcinoma
ADVANCED HEALTHCARE MATERIALS(2023)
Abstract
By conjugating a chemotherapeutic candidate drug 4 beta-NH-(5-aminoindazole)-podophyllotoxin (beta IZP) and an immunosuppressive protein galectin-1 targeted aptamer AP74, a chemo-immunotherapy molecule (AP74-beta IZP) is developed against liver cancer. AP74-beta IZP can target galectin-1 and enrich the tumor microenvironment to improve the tumor inhibition ratio by 6.3%, higher than that of beta IZP in a HepG2 xenograft model. In safety evaluation, beta IZP cannot be released from AP74-beta IZP in normal tissues with low glutathione level. Therefore, the degrees of organs injury and myelosuppression after the treatment with AP74-beta IZP are lower than those with beta IZP. After 21 d treatment at a drug dose of 5 mg kg(-1), AP74-beta IZP does not cause weight loss in mice, while the weight is significantly reduced by 24% and 14% from oxaliplatin and beta IZP, respectively. In immune synergy, AP74-IZP enhances CD4/CD8 cell infiltration to promote the expression of cell factor (i.e., IL-2, TNF-alpha, and IFN-gamma), which further improves the antitumor activity. The tumor inhibition ratio of AP74-beta IZP is 70.2%, which is higher than that of AP74 (35.2%) and beta IZP (48.8%). Because of the dual effects of chemotherapy and immunotherapy, AP74-beta IZP exhibits superior activity and lower toxicity. The approach developed in this work could be applicable to other chemotherapy drugs.
MoreTranslated text
Key words
hepatocellular carcinoma,aptamer,chemo‐immunotherapy
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined